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Dynamic contrast MRAbstract Objectives: Evaluating ESUR-proposed PI-RADS scoring system for prostate cancer
detection using multi-parametric MRI and comparing diagnostic performances of single and com-
bined scores.
Methods: 76 prostatic lesions in 54 patients prospectively assessed using mpMRI. T2, DWI, DCE,
MRS single, combined PI-RADS scores as well as PIRADS summed score for all four sequences
were recorded and histopathologically correlated.
Results: 61 out of 76 lesions were positive for cancer prostate. Peripheral zone lesions showed
PI-RADS sum score was highest AUC for Pca detection (Az = 0.923) while highest AUC for single
score was for DCE score (0.921). Best combined score was for T2 + DCE scores. Central gland
lesions showed highest AUC of 0.953 for PI-RADS sum score, and combined T2 + DWI score
showed highest AUC of 0.969. Single score with statistically significant AUC was T2 score
(Az = 0.875). Sum score in both PZ lesions and CG lesions showed no false positive results with
100% specificity for scores above 12.
Conclusions: PI-RADS scoring system and mpMRI have a promising role in Pca detection still
using single score resulted in lower diagnostic accuracy which improved for combined scores.
mpMRI results in CG showed controversies and need more evaluation in the future.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
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In the last decade, there has been a shift of interest in the
use of MRI from local staging to the detection and charac-
terization of primary foci of prostatic cancer (Pca) and with
more advances in the technology of MR imaging it becomes
able to provide functional tissue information combined with
anatomic information. To increase the accuracy, conven-
tional anatomic T2-weighted MR imaging was combined
with functional MR imaging techniques such as dynamic
contrast agent-enhanced MR imaging (DCE), diffusion-
weighted imaging (DWI), and MR spectroscopic imaging
(MRS) in an integrated multi-parametric MR imaging
(mpMRI) (1).
Each of which provides unique information on tissue
characteristics as DCE provides data on tissue perfusion
characteristics as well as tumor wash-in and wash-out con-
trast dynamics as tumors display increased angiogenesis
resulting in early and increased enhancement and rapid
washout (2). DWI records the Brownian motion of water
molecules within the tissue, based on the theory that neo-
plastic tissues show high cellular density and decreased
water movement (3,4). MR Spectroscopy examines cellular
metabolism, using measuring levels of choline and citrate
(5,6).
The rationale for the use of a multi-parametric approach
considered that any single sequence by itself has considerable
overlap between benign and malignant tissues; however, the
combination of sequences proved to have more predictive
power for cancer detection (7).
Many studies have evaluated the value of using various
functional prostatic MR imaging rather than just using the
conventional anatomical MR imaging alone. Several studies
had compared T2WI, DWI, DCE and MRS and demonstrated
that a combination of these methods can yield better diagnos-
tic accuracy for detecting Pca than any one modality alone
(3,8–10).
The great variations of the diagnostic role of multi-
parametric MRI in cancer prostate could be explained by the
complexity and contradictory findings of the different single
modalities which may result in a wide scope of possible inter-
pretations of findings leading to heterogeneous results. To
overcome these problems, the European Society of Urogenital
Radiology (ESUR) recently had called a panel of experts and
published a guideline providing recommendations for the per-
formance of mpMRI investigations and a structured reporting
scheme named Prostate Imaging Reporting and Data System
(PI-RADS) (13), inspired by the BI-RADS system for breast
cancer detection (11–14).
However, there is still debate regarding which functional
MR sequence has more diagnostic accuracy for prostate
detection after the implementation of the PIRADS scoring
system. So our purpose of this study was to evaluate the
use of the ESUR-proposed PI-RADS scoring system for
prostate cancer (Pca) detection using multi-parametric
MRI (mpMRI) in our clinical practice and to compare
the diagnostic performances of the single and combined
PI-RADS scores, and furthermore, to highlight the
differences of the diagnostic accuracy of each sequence in
relation to peripheral and transitional zones prostatic
cancer.2. Methods
2.1. Patients
Seventy-six prostatic lesions in 54 consecutive patients who
had clinical suspicion of cancer prostate (based on high PSA
level or suspicious digital rectal examination) were prospec-
tively assessed using 1.5T mpMRI including T2, DWI, DCE,
MRS sequences from time interval between 3-2013 and
9-2015. Confirmation of findings by laboratory and
histopathological data was obtained from either TRUS biopsy
or radical prostatectomy.
2.2. MR image acquisition protocol
The MR images were obtained with a 1.5-T closed magnet sys-
tem (Avanto; Siemens Medical Systems, Erlangen, Germany)
using phased array surface body coil (TORSO)-16 channels.
The imaging protocol was as follows:
1. T2-WI (SE images in-plane spatial resolution of
0.55  0.55 mm, 3500–4400/132 [repetition time msec/echo
time msec], 180 flip angle, 11–15 sections, 4-mm section
thickness, echo train length of 15, 220 field of view,
240  512 matrix) in three orthogonal planes covering the
prostate and the seminal vesicles.
2. DWI: (echo planar sequence) TR 2100/TE 80, Matrix
128  128, field of view 220 (±20), slice thickness 3 mm
without gap in between and 3 different b values (0, 800,
1000) . ADC maps were reconstructed on workstation for
qualitative and quantitative assessment.
3. 3D MR spectroscopy of entire prostate using a section-
selected box drawn all around the prostate. The matrix size
was 6  6  6 mm, the repetition time was 650 ms, and the
echo time was 120 ms. volume of interest (VOI) aligned to
axial T2WI; coverage of the whole prostate in the VOI; field
of view at least 1.5 voxels larger than VOI in all directions
to avoid wrap-around or back folding; spectral selective
suppression of water and lipid signals; positioning of at
least six fat saturation bands close to prostatic margin.
4. DCE MRI were obtained using fast 3D T1-weighted
gradient-echo images (T1-VIBE) (34/1.6, 14 flip angle, 10
transverse partitions on a 3D slab, 4-mm section thickness,
280-mm field of view, 77  256 matrix) acquired during an
intravenous bolus injection of a paramagnetic gadolinium
chelate – 0.1 mmol of gadopentetate dimeglumine (Mag-
nevist; Schering, Berlin, Germany) per kilogram of body
weight, that was administered using power injector at
2.5 mL/s, followed by a 20-mL saline flush. 3D volume
was acquired every 15 s for 10 min. Post processing includes
regions of interest (ROI), placement upon the suspected
lesions as well as the normal gland.
2.3. Image analysis
For reporting and localization of findings, the prostate was
divided into the apex, middle, and base of the gland compris-
ing 27 ROIs as recommended by the ESUR guidelines accord-
ing to a scheme presented by Roethke et al. (15)
Table 1 ROC curve of single PI-RADS scores for T2, DW,
DCE, MRS and for summed PIRADS score for cancer
detection in peripheral zone (on left) and in central gland (on
right).
PZ CG
AUC p AUC P
T2 score 0.805 0.002 0.875 0.042
DW score 0.748 0.012 0.781 0.126
DCE score 0.921 <0.001 0.828 0.075
MRS score 0.854 <0.001 0.781 0.126
T2 + DW+DCE+MRS 0.923 <0.001 0.953 0.014
Multi-parametric MRI and PI-RADS (V1) scoring system 1085All T2-WI, DWI, MRS and DCE MR data sets were
prospectively evaluated and scored. In a first step single-
scores from (1–5) for T2, DWI, DCE and MRS for each lesion
were defined according to the ESUR guidelines (13). Since the
diagnostic significance of the T2 sequences differs for the
peripheral and central glandular zone, 2 separate schemes were
recommended for each region that were used at current study.
For MRS the consensus described two methods a qualita-
tive (that was employed at the current study) and a quantita-
tive one. For DCE a qualitative method was used for
analysis depending on the shape of the signal intensity–time
curve (SI–t curve); In a type I curve, the SI gradually continues
to increase. Type II curves are characterized by SI stabilization
with a slight and late decrease. Type III curves show immedi-
ate washout after reaching peak enhancement. Then a PI-
RADS sum (PSsum) score (scale from 4 to 20) was calculated
by summation of the four previous single-scores.
2.4. Statistical analysis
Data were fed to the computer and analyzed using IBM SPSS
software package version 20.0. Agreement of the different pre-
dictives with the outcome was used and was expressed in sen-
sitivity, specificity, positive predictive value, negative
predictive value and accuracy. Receiver operating characteris-
tic (ROC) curve was plotted to analyze a recommended cutoff
based on Youden selected thresholds, and the area under the
ROC curve denotes the diagnostic performance of the test. A
p value of p< 0.05 was considered as statistically significant.
3. Results
In the current study 76 lesions were identified, 15 lesions were
confirmed to be non cancerous and 61 lesions were confirmed
to be foci of prostate cancer. Gleason score was histopatholog-
ically assigned for each malignant focus after either TRUS
biopsy (for 49 lesions) or radical prostatectomy (for 12 lesionsFig. 1 ROC curve of single PI-RADS scores for T2, DW, DCE, MRS
zone (on left) and in central gland (on right).in 7 patients). Twenty lesions showed Gleason score of <7
while 41 lesions showed Gleason P7. A whole amount of
pathology reports were obtained for the seven patients who
underwent robotic radical prostatectomy at Hospital Henri
Mondor in France.
3.1. Diagnostic performance of multiparametric-MRI for
prostate cancer detection in peripheral zone lesions and central
gland lesions
Peripheral zone lesions (n= 54) as well as central gland lesions
(n= 12) were assessed separately on T2, DWI, DCE and MRS
with excluding lesions involving both zones.
Analysis of receiver operator curve for the single PI-RADS
score of each sequence as well as the summed PI-RADS score
(PSsum) for detection of prostate cancer in peripheral zone
lesions (Fig. 1 and Table 1) showed the following:
 Summed PIRADS score of all the four sequences showed
the highest AUC for cancer detection (Az = 0.923). And
on using recommended Youden threshold of >12 for the
summed score, it showed the highest sensitivity of 83.72%
and highest specificity of 100%.and for summed PIRADS score for cancer detection in peripheral
1086 A.H. Afifi et al. The use of single MR sequences in detection of cancer in the
peripheral zone also led to lower AUC for prostate cancer
detection.
 Regarding single PI-RADS scores the AUC was also high-
est for DCE (0.921) followed by MRS, T2 and then DWI.
On using a selected threshold of >3 for each of the single
scores, the DWI showed highest sensitivity of 90.70% and
lowest specificity of 45.45%, while each of T2, DCE,
MRS showed lower sensitivity with significant higher speci-
ficity than DWI.
Detailed ROC evaluations of each score for all lesions are
shown in Fig. 1 and Tables 1 and 2.
Analysis of receiver operator curve for the single PI-RADS
score of each sequence as well as the summed PI-RADS score
(PSsum) for detection of prostate cancer in central gland lesions
(Fig. 1 and Table 1) showed the following:
 The only single PIRADS score that showed statistically sig-
nificant AUC value was for the T2 score with Az = 0.875 so
it was performed as the best single score in the central gland
lesions.
 However the summed PIRADS (PSsum) score of all the four
sequences combined still showed the highest AUC for can-
cer detection (Az = 0.923) compared to the T2 score.Table 2 Agreement (sensitivity, specificity and accuracy) in periphe
Pathology
Non cancerous Cancerou
T2 score 63 11 18
>3 0 25
DW score 63 5 4
>3 6 39
DCE score 63 11 16
>3 0 27
MRS score 63 10 10
>3 1 33
T2 + DW+DCE+MRS 612 11 7
>12 0 36
Table 3 Agreement (sensitivity, specificity and accuracy) in transiti
Pathology
Non cancerous Cancerous
T2 score 62 4 4
>2 0 4
DW score 63 2 0
>3 2 8
DCE score 63 3 3
>3 1 5
MRS score 63 4 3
>3 0 5
T2 + DW+DCE+MRS 612 4 1
>12 0 7 While Single PIRADS scores for DW, DCE and MRS each
alone was statistically insignificant in detection of central
gland lesions.
 Sensitivity and specificity were detected according to
selected thresholds and are shown in Table 3.
Analysis of receiver operator curve for T2 score with com-
binations of single PI-RADS scores as well as the summed PI-
RADS score (PSsum) for detection of prostate cancer in periph-
eral zone lesions (Fig. 2 and Table 4) showed the following:
 AUC for peripheral zone lesions only showed higher values
for combined T2 + DWI scores (Az = 0.855) when com-
pared to single T2 score (Az = 0.805).
 Also on adding DCE score, the combined score for T2
+ DWI + DCE showed higher AUC values (Az = 0.918)
than of the T2 + DWI scores only (Az = 0.923) denoting
better diagnostic accuracy.
 Still the summed PI-RADS score (PSsum) of all (T2
+ DWI + DCE+MRS) sequences showed the highest
AUC (Az = 0.923) for detection of prostate cancer in
peripheral zone lesions.
 When using the recommended Youden threshold of >3,
>7, >10 as well as >12 for the single T2 score, combined
T2 + DWI, combined T2 + DWI + DCE and for theral zone.
Sensitivity Specificity PPV NPV Accuracy
s
58.14 100.0 100.0 37.93 66.67
90.70 45.45 86.67 55.56 81.48
62.79 100.0 100.0 40.74 70.37
76.74 90.91 97.06 50.0 79.63
83.72 100.0 100.0 61.11 87.04
onal zone.
Sensitivity Specificity PPV NPV Accuracy
87.5 75.0 87.5 75.0 66.67
100.0 50.0 80.0 100.0 83.33
62.50 75.0 83.33 50.0 66.67
62.50 100.0 100.0 57.14 75.0
87.50 100.0 100.0 80.0 91.67
Fig. 2 ROC curves for T2, T2 + DW, T2 + DW+DCE and PSsum scores in cancer detection in peripheral zone (on left) and in central
gland (on right).
Table 4 ROC curves for T2, T2 + DW, T2 + DW+DCE
and PSsum scores in cancer detection in peripheral zone (on left)
and in central gland (on right).
PZ CG
AUC p AUC P
T2 score 0.805 0.002 0.875 0.42
T2 + DW 0.855 <0.001 0.969 0.011
T2 + DW+DCE 0.918 <0.001 0.938 0.017
T2 + DW+DCE+MRS 0.923 <0.001 0.953 0.014
Multi-parametric MRI and PI-RADS (V1) scoring system 1087PSsum respectively, it showed increased sensitivity and
ascending trend toward better diagnostic performance on
increasing combinations between scores, where sensitivity
was 58% for T2 score, 65% for combined T2 + DWI score,
76% for combined T2 + DWI +DCE score, 83% for
PSsum (T2 + DWI +DCE+MRS) and showed a speci-
ficity of 100% for all. This indicates increased diagnostic
performance and accuracy on using more score combina-
tions reaching the highest when using the summedTable 5 Agreement (sensitivity, specificity and accuracy) in periphe
Pathology
Non cancerous Cancerou
T2 score 63 11 18
>3 0 25
T2 + DW 67 11 15
>7 0 28
T2 + DW+DCE 610 11 10
>10 0 33
T2 + DW+DCE+MRS 612 11 7
>12 0 36PI-RADS score for all the sequences together. Detailed
ROC evaluations of each score for detection of peripheral
zone lesions are shown in Fig. 2 and Tables 4 and 5.
Analysis of receiver operator curve for T2 score with com-
binations of single PI-RADS scores as well as the summed PI-
RADS score (PSsum) for detection of prostate cancer in central
gland lesions (Fig. 2 and Table 4) showed the following:
 Adding DW score to T2 score had improved diagnostic
accuracy and performed as the best combination score in
detection of central gland lesions where it showed the high-
est AUC (Az = 0.969) which is significantly higher than
that of T2 score alone (Az = 0.875) which was performed
as the best single score.
 On adding DCE score to T2 + DW, it showed decrease in
the AUC to (Az = 0.938).
 On calculating the summed PIRADS (PSsum) score of the
four sequences combined the AUC (Az = 0.953) was also
less than that of T2 + DW scores but higher than T2
+ DW+DCE scores.ral zone.
Sensitivity Specificity PPV NPV Accuracy
s
58.14 100.0 100.0 37.93 66.67
65.12 100.0 100.0 42.31 72.22
76.74 100.0 100.0 52.38 84.48
83.72 100.0 100.0 61.11 87.04
Table 6 Agreement (sensitivity, specificity and accuracy) in transitional zone.
Pathology Sensitivity Specificity PPV NPV Accuracy
Non cancerous Cancerous
T2 score 63 4 4 50.0 100.0 100.0 50.0 66.67
>3 0 4
T2 + DW 67 4 2 75.0 100.0 100.0 66.67 83.33
>7 0 6
T2 + DW+DCE 610 4 2 75.0 100.0 100.0 66.67 83.33
>10 0 6
T2 + DW+DCE+MRS 612 4 1 87.50 100.0 100.0 80.0 91.67
>12 0 7
1088 A.H. Afifi et al. Sensitivity and specificity were detected according to
selected thresholds and are shown in Table 6.
Thus the PI-RADS sum score in both PZ lesions and CG
lesions showed no false positive results with 100% specificity
for scores above 12.
More of the PI-RADS score combinations were analyzed in
order to identify the best single score that should be added to
the T2 score as a first priority when there is no availability for
all sequences to improve the diagnostic performance of T2 in
both peripheral zone and central gland lesions (Figs. 3–7).
The DCE score was the best combination for the T2 score
regarding the peripheral zone lesions with an Az = 0.921 for
T2 + DCE combination, while regarding the central gland
lesions as expected from the above results the DWI was the
best combination for the T2 score with Az = 0.969.Fig. 3 Case (1): A 74-years male patient presented with LUTS and h
shows ill-defined hypointense lesion at the inferior aspect of the left ce
DWII shows hyperintense signals at high b value (800 s/mm2). (c)
0.5  103 cm s2. (DW score = 5) (d) DCE-MRI showing focal early en
contrast of the described lesion. (f) DCE-MRI regenerated curves with
3 curve +2 points for focal asymmetrical enhancement) (g) MRSI sho
score = 5). Conclusion: PI-RADS sum score of 18 consistent with a
biopsy showed Left prostatic adenocarcinoma with Gleason score 6(3At the selected Threshold of >6, the T2 + DCE combina-
tion at PZ showed sensitivity of 74.42% and specificity of
100% while the T2 + DW combination at CG showed sensi-
tivity of 75% and specificity of 100%. Detailed AUC values
for different combinations are shown in Table 7.
The frequency of the curve types used within the DCE score
for cancerous and non cancerous lesions was also studied and
there was a statistically significant difference between the two
groups with about 50% of the cancerous lesions which showed
type 3 curves and about 70% of the non cancerous lesions
which showed type 1 curves.
4. Discussion
Prostate Imaging Reporting and Data scoring system and
mpMRI have a promising role in Pca detection, and so theigh PSA (28 ng/ml), inconclusive DRE. mpMRI (a) T2 axial image
ntral zone (Segments 11a, 11p) with T2 score considered = 3. (b)
ADC map showing very low ADC value of the lesion around
hancement of contrast (e) DCE-MRI showing delayed washout of
type 3 curve (in solid line) (DCE score = 5 where 3 points for type
wing very high Cho relative to Ci and Cr levels (Cho Ci) (MRS
neoplastic focus of prostatic carcinoma. Histopathology: TRUS
+ 3).
Fig. 4 Case (2): 68-years male patient had LUTS and anal pain with right basal hard gland on DRE and PSA of 8.5 ng/ml. mpMRI (a)
Axial T2 FSE sequence showing well-defined hypointense focus (T2 score = 4), (b) The lesion exhibited hyperintensity in DWI at high b
value (800 s/mm2), (c) ADC map revealed low ADC value measuring around 0.6  103 cm s2. (DW score = 5) and (d) MRS revealed
high Cho relative to Ci and Cr levels (Cho > Ci). (MRS score (4) (e and f) DCE-MRI showing early focal enhancement and delayed
washout of contrast of the described lesion. (g) DCE-MRI regenerated curves with type 3 curve (in solid line) of the suspicious focus.
(DCE score = 5 where 3 points for type 3 curve +2 points for focal asymmetrical enhancement). Conclusion: mpMRI showed a PI-
RADS sum score of 18 reflecting focal nodule of prostatic carcinoma located in the right lobe, at its mid and basal segments (segments 4p
and 6p). Histopathology TRUS biopsy proved to be adenocarcinoma Gleason score 7 (4 + 3).
Multi-parametric MRI and PI-RADS (V1) scoring system 1089current study investigated different MR parameters recom-
mended by the ESUR regarding their individual as well as
their combined diagnostic performances. Current data showed
that the PI-RADS scoring system is a good tool to differentiate
Pca from non cancerous lesions showing higher probability of
Pca with higher PI-RADS scores. The use of single different
scores resulted in lower diagnostic accuracy with improved
accuracy for combined scores.
Regarding peripheral zone lesions, results of the current
study revealed that PI-RADS sum score for T2, DWI, DCE
and MRS showed the highest AUC for cancer detection
(Az = 0.923) and using a cut-off value 12, showed highest sen-
sitivity of 83.72% and highest specificity of 100%. Applying
single PI-RADS score in the peripheral zone led to lower
AUC for cancer detection. The highest AUC for single score
was for DCE score (0.921) followed by MRS. However,
DWI showed highest sensitivity of (90.70%) on using a
selected threshold of 3 for the single scores.
Our data showed increased sensitivity and diagnostic per-
formance on increasing combinations between scores as sensi-
tivity was 58% for T2 score, 65% for combined T2 + DWI
score, 76% for combined T2 + DWI + DCE score, 83% for
PSsum (T2 + DWI + DCE+MRS) and showed a specificity
of 100% for all and so reaching the highest performance when
using the summed PI-RADS score for all the sequencestogether. Analyzing different combinations showed best com-
bined score for cancer detection in PZ score was for combined
T2 + DCE scores.
This was concordant with results of previous studies who
evaluated PI-RADS scoring system using results of MRI
TRUS fusion biopsy (16), direct MRI-guided biopsy (17),
and radical prostatectomy as a reference standard (18), and
all stated that PI-RADS scoring system has a good diagnostic
performance with high sensitivities, and accuracies with high
inter-observer agreement. In all these studies, a sum score
has been used to integrate the individual scores for each
sequence in an overall score for a lesion. However, the optimal
cutoff values for a sum score ranged from 8 to 10 as they only
included T2, DW and DCE scores without using MRS score.
On the other hand, mpMRI results in the central gland
(CG) still show some controversy and need more evaluation
in the future. For CG lesions, PI-RADS sum score showed
high AUC of 0.953; however, the combination of T2 + DWI
score showed numerically the highest AUC of 0.969. The only
single score that showed statistically significant AUC was T2
score (Az = 0.875).
Chesnais et al. (19) showed that excellent characterization
of CG nodules could be achieved by combining T2 morpho-
logical features including homogeneous low signal intensity
at T2WI, lack of capsule, ill-defined margins with erased char-
Fig. 5 Case (3):66-years male patient had LURTS and right hard nodule on DRE (PSA was 24 ng/ml). mpMRI: (a and b) Axial and
Sagittal T2 FSE showed focal lesion at the basal and midzonal regions of right central zone displaying hypointensity typical for ‘‘erased
charcoal appearance” (T2 score = 4). (c) The lesion exhibited hyperintensity on DWI at high b value (800 s/mm2) and (d) Low ADC value
around 0.6  103 cm s2. (DW score = 5) (e and f) DCE-MRI showing focal early enhancement and delayed washout of contrast of the
suspicious focus. (g) DCE-MRI regenerated curves with type 3 curve (in solid line) of the suspicious focus. (DCE score = 5 where 3 points
for type 3 curve +2 points for focal asymmetrical enhancement). (h) MRS showing abnormal spectroscopic pattern with high Cho relative
to Ci and Cr levels (Cho > Ci). (MRS score = 4). Conclusion: mpMRI showed a PI-RADS sum score of 18 favoring prostatic carcinoma
along the right central zone of mid and basal gland (segments 3a–1a). Histopathology TRUS biopsy revealed adenocarcinoma Gleason
score 3 + 1, then Robotic radical prostatectomy was performed and confirmed the histopathology.
1090 A.H. Afifi et al.coal appearance, lenticular or amorphous shape and they sug-
gested these features are significant predictors of malignancy
among TZ nodules. At the same study, as in other studies
(20,21), ADC value was significantly lower in transitional can-
cers than in BPH nodules. Nevertheless, a large overlap of
ADC values was observed between benign and malignant nod-
ules. Furthermore, ADC value is known to be highly depen-
dent on the sequence parameters. This resulted in difficulty
in defining meaningful threshold to discriminate cancers
among TZ nodules, and so DWI might be of little help alone
in detecting and characterizing TZ tumors.
Our results were also matching with previous study by Baur
et al. (22), where they found that T2WI had the highest AUC
compared to other single scores and that addition of DWI to
T2WI had yielded a better diagnostic performance for cancer
detection in the TZ. This also was concordant with the findings
by Schimmoller et al. (23), where they analyzed Pca detection
in CG and stated that the combination of T2WI and DWI
Scores achieved the highest test accuracy.
In controversy with the results in the PZ, our results in the
central gland lesions showed that adding DCE score resulted
in reduction of AUC score with no improvement of diagnostic
performance for Pca detection. However, still statistical analy-
sis of our data regarding CG cancer is limited and lacking sta-
tistical power due to the small number of patients with pure
CG lesions.Schimmo¨ller et al. (23), stated that the DCE has a different
appearance regarding its localization and neglecting DCE in
TZ lesions could possibly be a key to better cancer detection.
However, for clinical routine, mpMRI excluding DCE cannot
be recommended due to the fact that additional benefit in read-
ing accuracy is depending on tumor location and grade.
In line with our results, studies by Baur et al. (22) and Kuru
et al. (24) had showed that the addition of DCE-MRI to a sum
score of T2WI and DWI did not substantially improve the
diagnostic performance. It is attributed to overlap with highly
vascularized BPH nodules in CG that showed enhancement
patterns similar to that of cancer and therefore limit the accu-
racy of DCE-MRI.
Conflicting results have been published regarding the value
of DCE imaging in detecting and characterizing TZ tumors.
Delongchamps et al. (25) found DCE-MRI decreases the accu-
racy of T2WI and DWI in the central gland without signifi-
cantly improving it in the peripheral zone. Kuru et al. (24)
stated that DCE did not add significant value to diagnosis of
Pca. However, other studies showed high sensitivity and speci-
ficity for DCE in detection and staging of Pca (26).
Junker et al. (27) stated that, it is doubtful whether DCE
has a diagnostic value for Pca detection in the TZ at all. In line
with the previous data, a degree of overlap for DCE in differ-
entiating Pca from benign prostatic hyperplasia has been
described (20). They also suggested that the PI-RADS has to
Fig. 6 Case (4): 56-years male patient had LUTS with PSA of 5.8 ng/ml and enlarged prostate on DRE. mpMRI: (a) Axial T2 FSE
revealed small nodule at the right PZ segments 3 and 4p. (T2 score = 3) and (b) The lesion showed isointense signals on DWI at high b
value. (c) ADC map showing low ADC value 0.8  103 cm s2. (DW score = 4) (d) MRS revealed normal spectroscopic pattern with high
Ci and low Cho levels (Ci Cho). (MRS score = 1) (e) DCE-MRI regenerated curves show type 1 curve (in solid line). (DCE score = 1).
Conclusion: mpMRI showed a PI-RADS sum score of 9 which lowers the risk of being prostatic neoplastic lesion. Histopathology TRUS
guided biopsy was performed and revealed chronic prostatitis with no malignant cells.
Multi-parametric MRI and PI-RADS (V1) scoring system 1091be improved regarding the DCE in TZ, possibly by using a dif-
ferent description for scores in PZ and in TZ, as has been done
for T2-weighted imaging.
Our results showed that PI-RADS overall for PZ lesions as
well as PI-RADS overall for CG lesions showed no false pos-
itive results with 100% specificity for the scores 4 and 5. These
go in line with the study by Boesen et al. (28), who stated that
there is highly significant correlation between positive biopsies
and lesion suspicion on mpMRI using PI-RADS classification.
If mpMRI showed a high suspicion of Pca on PI-RADS scor-
ing, then 89% (32 out of 36) were positive at biopsy. On the
other hand, only 6% (five out of 86) with PI-RADS low suspi-
cion on mpMRI were positive for Pca.
This goes well with the results by Junker et al. (27), who
showed that only 3 % of benign lesions have been scored with
PI-RADS 4 or 5, whereas 83 % of malignant lesions had such
high score levels. 100 % of high-grade Pca lesions were found
at score level of 4 or 5, concluding that an overall PI-RADS
score of 1 and 2 primarily revealed benign changes, and in
score 3, there was a certain amount of low-grade Pca, while
only high-grade cancer scored 4 or 5.
Current study limitations included the following. first we
only used whole gland pathology in 7 cases while the
histopathological data of the rest of lesions were dependingon the TRUS biopsy. Second, there was limited number of
pure central gland lesions which caused lack of significant
power regarding this group and that is attributed to that cen-
tral gland cancers are only representing 25–30% of prostate
cancer (29). Third, we have evaluated all sequences in the same
reading session. The appearance of a lesion in one sequence
might have affected its identification in another sequence
where bias resulting from the radiologist being aware of a
lesion depicted in other sequences would presumably lead to
an underestimation of differences in the diagnostic perfor-
mance of different sequences. However, in clinical routine,
the sequences of mpMRI data set are also evaluated together.
Finally we did not use endo-rectal coil due to high cost and
patient discomfort; meanwhile, it is recommended at 1.5T only
for MRS sequence which is still considered optional by ESUR
(13).
Using of PI-RADS scoring system and its new developing
experience is currently expanding where recent meta-analysis
by Hamoen et al. showed that there was one study from
2012 after the ESUR proposed the PI-RADS scoring system,
and there were eight studies from 2013 and five from the first
3 months of 2014 and ongoing (30).
So mpMRI is increasingly being recognized as a valuable
tool to assess prostate cancer and its role in clinical practice
Fig. 7 Case (5): A 76-years male patient presented with LUTS and high PSA (84 ng/ml), DRE showed firm left lobe with enlarged
seminal vesicle. mpMRI: Post TURP central prostatic defect with bilateral hypointense lesions involves the peripheral zones: (a) T2 axial
sequence revealed an ill-defined hypointense lesion at the right PZ (segment 3p) with intact prostatic capsule. (T2 score = 3) (b and c) T2
axial sequence shows another larger hypointense lesion at the left PZ (segment 7 and 9p) invading prostatic capsule, ipsilateral NVB and
SV. (T2 score = 5) (d) T2 coronal sequence shows the left sided lesion with SVI as well as pelvic bone deposits. (e and f) The left sided
lesion exhibited DWI hyperintensity with low ADC signals, measuring (0.6  103 mm2/s). (DW score = 5) (g and h) The right sided
lesion showed isointense signals on DWI and low ADC measuring (0.9  103 mm2/s). (DW score = 4) (i) DCE-MRI regenerated curves
show type 2 curve (in solid line) for the left sided lesion, (DCE score = 4 where 2 points for type 2 curve and +2 points for focal
asymmetrical enhancement), while it shows type 1 curve (dashed line) for the right sided lesion with no focal enhancement (DCE
score = 1) (j and k) MRS showing abnormal spectroscopic pattern of the left sided lesion with very high Cho relative to Ci and Cr levels
(Cho Ci) (MRS score = 5), while it shows preserved spectroscopic pattern of the right sided lesion with normal Ci levels (Ci Cho)
(MRS score = 1). Conclusion: mpMRI showed a PI-RADS sum score of 19 for the left sided lesion consistent with a neoplastic focus of
prostatic carcinoma, while it showed a PIRADS sum score of 9 for the left sided lesion which lowers the risk of prostatic cancerous lesion
on this side. Histopathology: TRUS biopsy showed left prostatic adenocarcinoma with Gleason score 7(4 + 3) and left seminal vesicle
involvement while it shows no cancerous lesions on the right side.
1092 A.H. Afifi et al.and guidelines is expanding not just for cancer staging but for
risk stratification and active surveillance. And in view of the
results of the current study we recommend extending the role
of mpMRI into the guidelines of early cancer detection.Conclusions of the current study showed that the PI-RADS
scoring system is a good tool to differentiate Pca from non
cancerous lesions showing higher probability of Pca with
higher PI-RADS scores. The use of single different scores
Table 7 AUC values for T2 PIRADS score and its combi-
nations for cancer detection in the peripheral zone and central
gland.
PZ CG
AUC p AUC P
T2 score 0.805 0.002 0.875 0.042
T2 + DW 0.855 <0.001 0.969 0.011
T2 + DCE 0.921 <0.001 0.891 0.034
T2 +MRS 0.887 <0.001 0.813 0.089
Multi-parametric MRI and PI-RADS (V1) scoring system 1093resulted in lower diagnostic accuracy with improved accuracy
for combined scores.
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